获取演示
Now livetag icon
The official Gen AI Landscape report for 2026 is here. Don’t miss out!Get your copybanner icon
Novo Holdings

七月 2026

七月 2026的Novo Holdings市场份额分析

Novo Holdings A/S is the Novo Nordisk Foundation's wholly owned holding company for Novo Nordisk A/S and Novozymes A/S. Novo Holdings A/S was established in 1999 and manages the Novo Nordisk Foundation's assets, which in 2023 was worth almost DKK 1,114 billion Danish Kroner.
成立年份1999
员工51 - 200
年营收> $1B
novoholdings.dk
Novo Holdings
Novo Holdings(包含公司地区分支机构)
  • novoholdings.dk
    novoholdings.dk
查看更多网站流量和参与度信息

Novo Holdings收入截至 七月 2026为 > 1B

Novo Holdings主要域名产生的收入

3 年中Novo Holdings主要域名的收入

Novo Holdings主要域名的收入


Novo Holdings热门域名的总访问量

了解Novo Holdings市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

子公司明细

Novo Holdings热门域名的平均访问时长

分析Novo Holdings参与度指标。

过去 3 个月的平均访问时长

子公司明细

Novo Holdings热门域名的平均页面浏览量

了解Novo Holdings如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

子公司明细

想要获取更深入的流量洞见?

过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。



Novo Holdings 采用的主要技术

这些是排名前 Novo Holdings 的顶级域名所使用的网站技术(按行业分列)

付费广告 (7)

DoubleClick

DoubleClick

内容管理系统 (5)

WordPress

WordPress

转化和分析 (4)

Google Analytics

Google Analytics

小部件 (4)

Google Maps

Google Maps

更多技术

8

查看全部

准备好发现优质潜在客户了吗?

借助 Similarweb 销售情报解决方案,确定任意网站使用了哪些技术来设计完美的销售宣传,并缩短销售周期。


Novo Holdings 的新闻与信号

借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。

新闻Novo Holdings invests into Crystalys Therapeutics Inc. $130M in Series B.With cash in hand from the Novo Holdings-contributed, Frazier Life Sciences-led financing, Crystalys will take several steps to establish dotinurad's potential role across the broader gout treatment paradigm, primarily in the second-line setting.
新闻Novo Holdings partnered with Invest Europe LP on Jan 1st '26.Earlier this year, a group of European VCs, including Denmark's Novo Holdings and France's Sofinnova Partners, launched The European Life Sciences Coalition in partnership with Invest Europe, calling for more capital, both public and private, to be injected into the region.
新闻Novo Holdings invests into cAMPfield Therapeutics, Inc. $180M in Series A.cAMPfield Therapeutics has emerged with a $180 million Series A financing to develop prifemilast, a once-daily oral PDE4B-selective inhibitor, for inflammatory bowel disease.[2] The round was led by Frazier Life Sciences and included Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, and RA Capital.

查看 Novo Holdings 的所有信号

让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。